Olanzapin Actavis (Olanzapine)

Olanzapine, the active ingredient in Olanzapin Actavis, is an atypical antipsychotic presented as a tablet for oral use. It is used to manage symptoms of schizophrenia and bipolar disorder in adult patients.

GNH USA supplies Olanzapin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is an atypical antipsychotic that modulates neurotransmitter activity in several psychiatric disorders. - Schizophrenia: Reduces positive and negative symptoms and helps prevent relapse. - Bipolar I disorder (manic episodes): Controls acute mania and maintains mood stability. - Bipolar II disorder (depressive episodes): Used as adjunctive therapy to improve depressive symptoms. - Schizoaffective disorder: Alleviates psychotic features and mood disturbances.

Olanzapine may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Weight gain: Increased appetite leading to moderate weight increase. - Sedation: Drowsiness or feeling of tiredness. - Dry mouth: Reduced salivation. - Constipation: Decreased bowel motility. - Orthostatic hypotension: Light‑headedness on standing. - Elevated prolactin: Mild hormonal changes.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: Fever, muscle rigidity, autonomic instability. - Tardive dyskinesia: Involuntary, repetitive movements. - Severe hyperglycaemia or new‑onset diabetes mellitus. - Agranulocytosis: Marked reduction in white‑blood cell count. - Myocardial infarction or other cardiac events. - Seizures: New or worsening seizure activity.

When prescribing Olanzapine, clinicians should consider several safety aspects. - Metabolic monitoring: Regularly assess weight, fasting glucose and lipid profile. - Cardiovascular assessment: Monitor blood pressure and heart rate, especially at treatment initiation. - CNS depression: Caution in patients operating machinery or driving. - Pregnancy and lactation: Evaluate risk‑benefit; use only if clearly needed. - Elderly with dementia-related psychosis: Increased risk of mortality. Store at below 25°C: keep in the original packaging, protect from moisture and light.

Olanzapine interacts with several drug classes that may require dose adjustment or monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) – increase olanzapine exposure. - Strong CYP1A2 inducers (e.g., rifampicin) – reduce olanzet 

Moderate  t   ");